IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza

PLoS Pathogens

Volumn 10, Issue 12, 2014, Pages

  Egli, Adrian ^a,b   Santer, Deanna M ^b   O'Shea, Daire ^b,c   Barakat, Khaled ^b,c   Syedbasha, Mohammedyaseen ^a   Vollmer, Madeleine ^a   Baluch, Aliyah ^d   Bhat, Rakesh ^b   Groenendyk, Jody ^e   Joyce, Michael A ^b   Lisboa, Luiz F ^b   Thomas, Brad S ^b   Battegay, Manuel ^a,f   Khanna, Nina ^a,f   Mueller, Thomas ^g   Tyrrell, D Lorne J ^b   Houghton, Michael ^b   Humar, Atul ^h   Kumar, Deepali ^h  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL VACCINE; INFLUENZA VACCINE; INTERLEUKIN 28; INTERLEUKIN 28B; T CELL VACCINE; UNCLASSIFIED DRUG; HLA DR ANTIGEN; IL28B PROTEIN, HUMAN; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN DERIVATIVE; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 TH2 BALANCE; ADULT; AGED; B LYMPHOCYTE; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; GENETICS; GRAFT RECIPIENT; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; IN VITRO STUDY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ADULT; AGED; B-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IN VITRO TECHNIQUES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERLEUKIN-4; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TRANSPLANT RECIPIENTS;

EID: 84919663450     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004556     Document Type: Article

References (58)

1. Medina RA, Garcia-Sastre A, (2011) Influenza A viruses: new research developments. Nat Rev Microbiol 9: 590–603.
2. Centers for Disease C, Prevention (2013) Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices–United States, 2013–2014. MMWR Recomm Rep 62: 1–43.
3. Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY, (2012) Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 30: 1413–1424.
4. Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS, (2012) Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 206: 1250–1259.
5. Nicoll A, Sprenger M, (2013) Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis 13: 7–9.
6. Le Corre N, Thibault F, Pouteil Noble C, Meiffredy V, Daoud S, et al. (2012) Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine 30: 7522–7528.
7. Salles MJ, Sens YA, Malafronte P, Souza JF, Vilas Boas LS, et al. (2012) Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients. Transpl Infect Dis 14: 564–574.
8. Kollmann TR, (2013) Variation between Populations in the Innate Immune Response to Vaccine Adjuvants. Front Immunol 4: 81.
9. Pashine A, Valiante NM, Ulmer JB, (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11: S63–68.
10. Bucasas KL, Franco LM, Shaw CA, Bray MS, Wells JM, et al. (2011) Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 203: 921–929.
11. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12: 786–795.
12. Obermoser G, Presnell S, Domico K, Xu H, Wang Y, et al. (2013) Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38: 831–844.
13. Miller MS, Palese P, (2014) Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 157: 294–299.
14. Booth D, George J, (2013) Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C. Nat Genet 45: 119–120.
15. Kelly C, Klenerman P, Barnes E, (2011) Interferon lambdas: the next cytokine storm. Gut 60: 1284–1293.
16. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77.
17. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, et al. (2009) Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 64: 375–386.
18. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G, (2009) IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113: 5829–5838.
19. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, et al. (2007) Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 8: 254–261.
20. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, et al. (2011) IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 3: 348–361.
21. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, et al. (2008) Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 125: 492–502.
22. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, et al. (2012) Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One 7: e44915.
23. Mennechet FJ, Uze G, (2006) Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107: 4417–4423.
24. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338–1337, 1338-1345, 1345 e1331-1337.
25. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
26. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100–1104.
27. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
28. Baluch A, Humar A, Eurich D, Egli A, Liacini A, et al. (2013) Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant 13: 1026–1033.
29. Egli A, Levin A, Santer DM, Joyce M, O'Shea D, et al. (2014) Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus. J Infect Dis
30. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140: 1021–1031.
31. Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, et al. (2013) Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes. Hepatology
32. Rallon NI, Soriano V, Naggie S, Restrepo C, McHutchison J, et al. (2012) Impact of IL28B gene polymorphisms on interferon-lambda3 plasma levels during pegylated interferon-alpha/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother 67: 1246–1249.
33. Shi X, Pan Y, Wang M, Wang D, Li W, et al. (2012) IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 7: e37054.
34. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, et al. (2013) Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog 9: e1003316.
35. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, et al. (2012) Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 189: 2735–2745.
36. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, et al. (2010) Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 207: 2703–2717.
37. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, et al. (2007) Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 8: 13–20.
38. Pritchard AL, White OJ, Burel JG, Upham JW, (2012) Innate interferons inhibit allergen and microbial specific T(H)2 responses. Immunol Cell Biol 90: 974–977.
39. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, et al. (2010) Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J Mol Biol 404: 650–664.
40. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, et al. (2013) Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 5: 176ra132.
41. Witte K, Witte E, Sabat R, Wolk K, (2010) IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 21: 237–251.
42. Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM, (2008) IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181: 8576–8584.
43. Swain SL, McKinstry KK, Strutt TM, (2012) Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 12: 136–148.
44. Egli A, Santer MD, O'Shea D, Tyrrell DL, Houghton M, (2014) The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Infect Dis e51.
45. Bravo D, Solano C, Gimenez E, Remigia MJ, Corrales I, et al. (2013) Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol
46. Cui W, Sun CM, Deng BC, Liu P, (2013) Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: a meta-analysis. Gene 525: 35–40.
47. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz VS, et al. (2011) Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 29: 7883–7895.
48. Salles MJ, Sens YA, Boas LS, Machado CM, (2010) Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 24: E17–23.
49. Egli A, Kumar D, Broscheit C, O'Shea D, Humar A, (2013) Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 95: 448–455.
50. Honda K, Taniguchi T, (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6: 644–658.
51. Lohoff M, Mak TW, (2005) Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5: 125–135.
52. Toporovski R, Morrow MP, Weiner DB, (2010) Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther 10: 1489–1500.
53. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, et al. (2014) IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med
54. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
55. Thomas BS, Joyce MA, Levin A, Tyrrell DL, (2014) Validation of TaqMan SNP genotyping specificity for rs12979860 of IL-28B: Modeling primer specificity in vitro. J Virol Methods
56. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, et al. (2009) Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 284: 20869–20875.
57. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH, (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5: e8668.
58. Egli A, Silva M, JrO'Shea D, Wilson LE, Baluch A, et al. (2012) An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One 7: e43937.